Abstract
Blackleg, caused by Leptosphaeria maculans , is a major disease affecting oilseed rape ( Brassica napus ) worldwide. The use of fungicides is an essential tool for disease management; however, limited information is available regarding L. maculans sensitivity to fungicides in Argentina. In this study, the sensitivity of L. maculans isolates collected from five oilseed rape-growing regions in Argentina was evaluated against three fungicides with different modes of action: prothioconazole (DMI), azoxystrobin (QoI), and boscalid (SDHI). The effective concentration required to inhibit mycelial growth by 50% (EC 50 ) was determined using in vitro assays. Mean EC 50 values for prothioconazole, azoxystrobin, and boscalid were 0.1545 µg mL -1 , 0.0349 µg mL -1 , and 0.1557 µg mL -1 , respectively. A wider variability in sensitivity was observed for azoxystrobin and boscalid compared to prothioconazole. Additionally, discriminatory dose assays revealed significant differences in growth inhibition among isolates, with some showing reduced sensitivity. Spearman correlation analysis indicated a significant positive association between azoxystrobin and boscalid sensitivity at both low and high doses, suggesting potential cross-resistance. However, no significant correlations were found between prothioconazole and the other fungicides. Furthermore, isolates with reduced sensitivity (RSI < 1) did not exhibit a consistent cross-resistance pattern between QoI and SDHI fungicides, indicating that the observed correlations may be influenced by the overall distribution of sensitive isolates rather than a shared resistance mechanism. These findings provide the first insights into L. maculans fungicide sensitivity in Argentina, highlighting the need for continued monitoring to prevent resistance development and ensure effective blackleg management.
Full text
1,933 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
Blackleg, caused by Leptosphaeria maculans, is a major disease affecting oilseed rape (Brassica napus) worldwide. The use of fungicides is an essential tool for disease management; however, limited information is available regarding L. maculans sensitivity to fungicides in Argentina. In this study, the sensitivity of L. maculans isolates collected from five oilseed rape-growing regions in Argentina was evaluated against three fungicides with different modes of action: prothioconazole (DMI), azoxystrobin (QoI), and boscalid (SDHI). The effective concentration required to inhibit mycelial growth by 50% (EC50) was determined using in vitro assays. Mean EC50 values for prothioconazole, azoxystrobin, and boscalid were 0.1545 µg mL-1, 0.0349 µg mL-1, and 0.1557 µg mL-1, respectively. A wider variability in sensitivity was observed for azoxystrobin and boscalid compared to prothioconazole. Additionally, discriminatory dose assays revealed significant differences in growth inhibition among isolates, with some showing reduced sensitivity. Spearman correlation analysis indicated a significant positive association between azoxystrobin and boscalid sensitivity at both low and high doses, suggesting potential cross-resistance. However, no significant correlations were found between prothioconazole and the other fungicides. Furthermore, isolates with reduced sensitivity (RSI < 1) did not exhibit a consistent cross-resistance pattern between QoI and SDHI fungicides, indicating that the observed correlations may be influenced by the overall distribution of sensitive isolates rather than a shared resistance mechanism. These findings provide the first insights into L. maculans fungicide sensitivity in Argentina, highlighting the need for continued monitoring to prevent resistance development and ensure effective blackleg management.
Competing Interest Statement
The authors have declared no competing interest.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.